·
·
Tech & Science
A new non-hormonal method temporarily halts sperm production in mice using a cancer research molecule, offering a potential reversible male contraceptive.
A team of scientists has developed a technique to temporarily and safely halt sperm production without damaging surrounding tissue, a breakthrough that could revolutionize male contraception. The method addresses a critical gap in available options, as men currently rely primarily on condoms or vasectomies.
While vasectomies are theoretically reversible, many men are hesitant to undergo the procedure. This has made the development of non-hormonal methods to temporarily suspend sperm production a highly sought-after goal, often described as the "holy grail" of contraceptive research.
Researchers conducted the study over six years on mice, publishing their findings in the journal PNAS. They utilized a small molecule called JQ1, originally developed as a research tool for studying cancer. The molecule was found to interfere with a specific stage of meiosis—the process responsible for producing sex cells—effectively halting the formation of sperm.
JQ1 disrupted meiosis by eliminating cells in the first phase of division and blocking the genetic activity necessary for later phases. When male mice were given the molecule for three weeks, sperm production stopped completely.
After treatment was discontinued, sperm production returned to normal levels within six weeks. The treated mice were able to reproduce and father healthy offspring, which were also capable of reproduction.
Dr. Paula Cohen, a geneticist and co-author of the study, stated that her team is practically the only group promoting the idea that targeting the testicles is a viable approach to contraception. She explained that their research demonstrates the restoration of normal meiosis and full sperm function, and, critically, that the offspring are born completely normal.
In future studies, the researchers aim to develop a new form of male contraception administered as an injection every three months. While acknowledging the need for further safety evaluations, they believe their study provides a blueprint for developing new contraceptive methods that operate safely within germ cells.
